Tweet
Ibrutinib is an antineoplastic drug used to treat chronic lymphocytic leukemia, mantle cell lymphoma. Ibrutinib is a small molecule that acts as an irreversible and potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and has shown potential activity against B-cell malignancies in clinical trials. Ibrutinib was developed commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma. This is really not affordable for all patients. You can get complete information about Ibrutinib cost on Medixo Centre.